The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures

Journal of Neuroimmunology

Volumn 283, Issue , 2015, Pages 11-16

  Zilkha Falb, R ^a   Gurevich, M ^a   Hayardeny, L ^c   Achiron, A ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c TEVA PHARMACEUTICALS   (Israel)

Author keywords

Gene expression microarray; Laquinimod; Multiple sclerosis; Peripheral blood mononuclear cells

Indexed keywords

ALPHA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON ALPHA 10; INTERFERON ALPHA 17; INTERFERON ALPHA 4; INTERFERON ALPHA 8; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 20; INTERLEUKIN 36; INTERLEUKIN 9; INTERLEUKIN RECEPTOR; LAQUINIMOD; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CYTOKINE; IMMUNOLOGIC FACTOR; MESSENGER RNA; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL MOTION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; DRUG MECHANISM; FEMALE; GENE EXPRESSION REGULATION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE EXTRAVASATION; LEUKOCYTE MIGRATION; MALE; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; NEUTROPHIL CHEMOTAXIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TREATMENT DURATION; BIOSYNTHESIS; BLOOD; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ADULT; CELL ADHESION; CHEMOTAXIS, LEUKOCYTE; CYTOKINES; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NF-KAPPA B; QUINOLONES; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84929598546     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2015.04.007     Document Type: Article

References (48)

1. Adams R.A., Bauer J., Flick M.J., Sikorski S.L., Nuriel T., Lassmann H., Degen J.L., Akassoglou K. The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J. Exp. Med. 2007, 204:571-582.
2. Adams R.A., Schachtrup C., Davalos D., Tsigelny I., Akassoglou K. Fibrinogen signal transduction as a mediator and therapeutic target in inflammation: lessons from multiple sclerosis. Curr. Med. Chem. 2007, 14:2925-2936.
3. Akassoglou K. Coagulation takes center stage in inflammation. Blood 2015, 125:419-420.
4. Akassoglou K., Yu W.M., Akpinar P., Strickland S. Fibrin inhibits peripheral nerve remyelination by regulating Schwann cell differentiation. Neuron 2002, 33:861-875.
5. Akassoglou K., Adams R.A., Bauer J., Mercado P., Tseveleki V., Lassmann H., Probert L., Strickland S. Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:6698-6703.
6. Bartolome R.A., Sanz-Rodriguez F., Robledo M.M., Hidalgo A., Teixido J. Rapid up-regulation of alpha4 integrin-mediated leukocyte adhesion by transforming growth factor-beta1. Mol. Biol. Cell 2003, 14:54-66.
7. Brill A., Franitza S., Lider O., Hershkoviz R. Regulation of T-cell interaction with fibronectin by transforming growth factor-beta is associated with altered Pyk2 phosphorylation. Immunology 2001, 104:149-156.
8. Bruck W., Vollmer T. Multiple sclerosis: oral laquinimod for MS-bringing the brain into focus. Nat. Rev. Neurol. 2013, 9:664-665.
9. Brück W., Wegner C. Insight into the mechanism of laquinimod action. J. Neurol. Sci. 2011, 306:173-179.
10. Bruck W., Pfortner R., Pham T., Zhang J., Hayardeny L., Piryatinsky V., Hanisch U.K., Regen T., van Rossum D., Brakelmann L., Hagemeier K., Kuhlmann T., Stadelmann C., John G.R., Kramann N., Wegner C. Reduced astrocytic NF-kappaB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012, 124:411-424.
11. Brunmark C., Runstrom A., Ohlsson L., Sparre B., Brodin T., Astrom M., Hedlund G. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2002, 130:163-172.
12. Comi G., Pulizzi A., Rovaris M., Abramsky O., Arbizu T., Boiko A., Gold R., Havrdova E., Komoly S., Selmaj K., Sharrack B., Filippi M., Group L.A.Q.S. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 371:2085-2092.
13. Davalos D., Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin. Immunopathol. 2012, 34:43-62.
14. Davalos D., Baeten K.M., Whitney M.A., Mullins E.S., Friedman B., Olson E.S., Ryu J.K., Smirnoff D.S., Petersen M.A., Bedard C., Degen J.L., Tsien R.Y., Akassoglou K. Early detection of thrombin activity in neuroinflammatory disease. Ann. Neurol. 2014, 75:303-308.
15. East E., Gverić D., Baker D., Pryce G., Lijnen H., ML., C. Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation. Neuropathol. Appl. Neurobiol. 2008, 34:16-30.
16. Filippi M., Rocca M.A., Pagani E., De Stefano N., Jeffery D., Kappos L., Montalban X., Boyko A.N., Comi G. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J. Neurol. Neurosurg. Psychiatry 2014, 85:851-858. Group, A.S.
17. Gasperini C., Ruggieri S., Pozzilli C. Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets. Ther. Clin. Risk Manag. 2010, 6:391-399.
18. Ghoreschi K., Laurence A., Yang X.P., Tato C.M., McGeachy M.J., Konkel J.E., Ramos H.L., Wei L., Davidson T.S., Bouladoux N., Grainger J.R., Chen Q., Kanno Y., Watford W.T., Sun H.W., Eberl G., Shevach E.M., Belkaid Y., Cua D.J., Chen W., O'Shea J.J. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 2010, 467:967-971.
19. Gurevich, M.; Gritzman, T.; Orbach, R.; Tuller, T.; Feldman, A.; Achiron, A. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study. J. Neuroimmunol. 2010, 221:87-94.
20. Gutcher I., Donkor M.K., Ma Q., Rudensky A.Y., Flavell R.A., Li M.O. Autocrine transforming growth factor-beta1 promotes in vivo Th17 cell differentiation. Immunity 2011, 34:396-408.
21. Gveric D., Herrera B., Petzold A., Lawrence D., Cuzner M. Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain 2003, 126.
22. Horwitz D.A., Zheng S.G., Gray J.D. The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsets. J. Leukoc. Biol. 2003, 74:471-478.
23. Hummon A.B., Lim S.R., Difilippantonio M.J., Ried T. Isolation and solubilization of proteins after TRIzol extraction of RNA and DNA from patient material following prolonged storage. Biotechniques 2007, 42(467-470):472.
24. Jadidi-Niaragh F., Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand. J. Immunol. 2011, 74:1-13. (Jul;74(1):1-13., S.J.I.).
25. Jolivel V., Luessi F., Masri J., Kraus S.H., Hubo M., Poisa-Beiro L., Klebow S., Paterka M., Yogev N., Tumani H., Furlan R., Siffrin V., Jonuleit H., Zipp F., Waisman A. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain 2013, 136:1048-1066.
26. Lee Y., Awasthi A., Yosef N., Quintana F.J., Xiao S., Peters A., Wu C., Kleinewietfeld M., Kunder S., Hafler D.A., Sobel R.A., Regev A., Kuchroo V.K. Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 2012, 13:991-999.
27. Lee P.W., Yang Y., Racke M.K., Lovett-Racke A.E. Analysis of TGF-beta1 and TGF-beta3 as regulators of encephalitogenic Th17 cells: implications for multiple sclerosis. Brain Behav. Immun. 2014, 10.1016/j.bbi.2014.12.007.
28. Lunemann J.D., Aktas O., Gniadek P., Zschenderlein R., Zipp F. Downregulation of transforming growth factor-beta1 in interferon-beta1a-treated MS patients. Neurology 2001, 57:1132-1134.
29. Luo D.D., Fielding C., Phillips A., Fraser D. Interleukin-1 beta regulates proximal tubular cell transforming growth factor beta-1 signalling. Nephrol. Dial. Transplant. 2009, 24:2655-2665.
30. Meng Q., Zheng M., Liu H., Song C., Zhang W., Yan J., Qin L., Liu X. SASH1 regulates proliferation, apoptosis, and invasion of osteosarcoma cell. Mol. Cell. Biochem. 2013, 373:201-210.
31. Murphy T.L., Cleveland M.G., Kulesza P., Magram J., Murphy K.M. Regulation of interleukin 12 p40 expression through an NF-kappa B half-site. Mol. Cell. Biol. 1995, 15:5258-5267.
32. Oh S.A., Li M.O. TGF-beta: guardian of T cell function. J. Immunol. 2013, 191:3973-3979.
33. Ponighaus C., Ambrosius M., Casanova J.C., Prante C., Kuhn J., Esko J.D., Kleesiek K., Gotting C. Human xylosyltransferase II is involved in the biosynthesis of the uniform tetrasaccharide linkage region in chondroitin sulfate and heparan sulfate proteoglycans. J. Biol. Chem. 2007, 282:5201-5206.
34. Ruffini F., Rossi S., Bergamaschi A., Brambilla E., Finardi A., Motta C., Studer V., Barbieri F., De Chiara V., Hayardeny L., Comi G., Centonze D., Martino G. Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. Mult. Scler. 2013, 19:1084-1094.
35. Sanjabi S., Zenewicz L.A., Kamanaka M., Flavell R.A. Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr. Opin. Pharmacol. 2009, 9:447-453.
36. Schachtrup C., Lu P., Jones L.L., Lee J.K., Lu J., Sachs B.D., Zheng B., Akassoglou K. Fibrinogen inhibits neurite outgrowth via beta 3 integrin-mediated phosphorylation of the EGF receptor. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11814-11819.
37. Schachtrup C., Ryu J.K., Helmrick M.J., Vagena E., Galanakis D.K., Degen J.L., Margolis R.U., Akassoglou K. Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage. J. Neurosci. 2010, 30:5843-5854.
38. Schulze-Topphoff U., Shetty A., Varrin-Doyer M., Molnarfi N., Sagan S.A., Sobel R.A., Nelson P.A., Zamvil S.S. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One 2012, 7:e33797.
39. Takami M., Love R.B., Iwashima M. TGF-beta converts apoptotic stimuli into the signal for Th9 differentiation. J. Immunol. 2012, 188:4369-4375.
40. Toubi E., Nussbaum S., Staun-Ram E., Snir A., Melamed D., Hayardeny L., Miller A. Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis. J. Neuroimmunol. 2012, 251:45-54.
41. Varrin-Doyer M., Zamvil S.S., Schulze-Topphoff U. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp. Neurol. 2014, 262(PA):66-71.
42. Vos C.M., Geurts J.J., Montagne L., van Haastert E.S., Bo L., van der Valk P., Barkhof F., de Vries H.E. Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol. Dis. 2005, 20:953-960.
43. Wan Y.Y., Chi H., Xie M., Schneider M.D., Flavell R.A. The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. Nat. Immunol. 2006, 7:851-858.
44. Wegner C., Stadelmann C., Pfortner R., Raymond E., Feigelson S., Alon R., Timan B., Hayardeny L., Bruck W. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2010, 227:133-143.
45. Yang J.S., Xu L.Y., Xiao B.G., Hedlund G., Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J. Neuroimmunol. 2004, 156:3-9.
46. Yang Y., Weiner J., Liu Y., Smith A.J., Huss D.J., Winger R., Peng H., Cravens P.D., Racke M.K., Lovett-Racke A.E. T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J. Exp. Med. 2009, 206:1549-1564.
47. Yoshida Y., Yoshimi R., Yoshii H., Kim D., Dey A., Xiong H., Munasinghe J., Yazawa I., O'Donovan M.J., Maximova O.A., Sharma S., Zhu J., Wang H., Morse H.C., Ozato K. The transcription factor IRF8 activates integrin-mediated TGF-beta signaling and promotes neuroinflammation. Immunity 2014, 40:187-198.
48. Zou L.P., Abbas N., Volkmann I., Nennesmo I., Levi M., Wahren B., Winblad B., Hedlund G., Zhu J. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 2002, 42:731-739.